| Not Yet Recruiting | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults NCT07516353 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma NCT07514819 | St. Jude Children's Research Hospital | N/A |
| Recruiting | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas NCT06465199 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Recruiting | Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) NCT07297979 | Amgen | Phase 1 |
| Not Yet Recruiting | Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma NCT07321912 | Milton S. Hershey Medical Center | Phase 2 |
| Recruiting | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190 | University of Florida | Phase 1 / Phase 2 |
| Recruiting | Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABR NCT07172958 | Children's National Research Institute | Phase 1 |
| Recruiting | Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refracto NCT07222735 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies NCT07197554 | SEED Therapeutics, Inc. | Phase 1 |
| Recruiting | Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial NCT07188532 | Mayo Clinic | N/A |
| Recruiting | A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors NCT06926283 | Hangzhou DAC Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastati NCT06827717 | Sun Yat-sen University | Phase 2 |
| Recruiting | Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma NCT06796543 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Recruiting | Fertility Preservation in Children With Solid Tumors: Detection of Residual Disease by a Sensitive Method NCT07141862 | University Hospital, Clermont-Ferrand | — |
| Recruiting | A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppressio NCT06699472 | Fudan University | Phase 2 |
| Recruiting | Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors NCT06541262 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Recruiting | A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma NCT06564272 | Beijing Konruns Pharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its NCT06850506 | Peking University People's Hospital | — |
| Recruiting | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or NCT06395103 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study NCT06451302 | Yizhuo Zhang | N/A |
| Active Not Recruiting | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants NCT06566092 | Iovance Biotherapeutics, Inc. | Phase 1 |
| Recruiting | Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma NCT06340204 | Peking University People's Hospital | Phase 1 |
| Recruiting | Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma NCT06243588 | Istituto Ortopedico Rizzoli | — |
| Recruiting | Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas NCT06156410 | Children's Hospital of Philadelphia | Phase 1 |
| Recruiting | To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) NCT05968768 | Anna Raciborska | Phase 2 |
| Recruiting | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) NCT06094101 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Recruiting | Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy NCT06029218 | Centre Antoine Lacassagne | N/A |
| Recruiting | Lurbinectedin in FET-Fused Tumors NCT05918640 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma NCT05830084 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 |
| Recruiting | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sa NCT05734066 | Jazz Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Use of GnRHa During Chemotherapy for Fertility Protection NCT05328258 | Kenny Rodriguez-Wallberg | Phase 3 |
| Terminated | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours NCT05605522 | 3B Pharmaceuticals GmbH | Phase 1 |
| Recruiting | Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salva NCT05779670 | Istituto Ortopedico Rizzoli | — |
| Withdrawn | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors NCT04791228 | Children's National Research Institute | Phase 2 |
| Recruiting | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3 NCT04897321 | St. Jude Children's Research Hospital | Phase 1 |
| Recruiting | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas NCT05182164 | Institut Bergonié | Phase 2 |
| Completed | A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small R NCT05275426 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors NCT05302921 | Children's National Research Institute | Phase 2 |
| Recruiting | Early Ageing During Therapy in AYA Cancer Patients NCT05062707 | University Medical Center Groningen | — |
| Unknown | A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) NCT05266196 | Salarius Pharmaceuticals, LLC | Phase 1 / Phase 2 |
| Recruiting | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced NCT04995003 | Baylor College of Medicine | Phase 1 |
| Completed | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With NCT05093322 | Hutchmed | Phase 1 / Phase 2 |
| Recruiting | Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Sol NCT04337177 | Valent Technologies, LLC | Phase 1 |
| Terminated | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and You NCT04730349 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Unknown | Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma NCT04735289 | Istituto Ortopedico Rizzoli | — |
| Recruiting | Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse NCT04758000 | Istituto Ortopedico Rizzoli | Phase 2 |
| Completed | SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarc NCT04067115 | Sarcoma Alliance for Research through Collaboration | Phase 1 / Phase 2 |
| Completed | Drug Sensitivity and Mutation Profiling NCT04956198 | Florida International University | — |
| Withdrawn | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma NCT03880123 | Matthew Ingham | Phase 1 |
| Completed | Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma NCT06851221 | Meyer Children's Hospital IRCCS | N/A |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Unknown | Combination Immunotherapy Targeting Sarcomas NCT04433221 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sar NCT04055220 | Centre Leon Berard | N/A |
| Terminated | Palbociclib + Ganitumab In Ewing Sarcoma NCT04129151 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Active Not Recruiting | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors NCT03709680 | Pfizer | Phase 2 |
| Active Not Recruiting | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and NCT03478462 | Cellectar Biosciences, Inc. | Phase 1 |
| Terminated | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors NCT03604783 | Sumitomo Pharma America, Inc. | Phase 1 |
| Recruiting | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas NCT03715933 | Inhibrx Biosciences, Inc | Phase 1 |
| Terminated | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomi NCT03495921 | Gradalis, Inc. | Phase 3 |
| Unknown | Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcom NCT03600649 | Salarius Pharmaceuticals, LLC | Phase 1 |
| Recruiting | Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD NCT06068075 | Dana-Farber Cancer Institute | N/A |
| Terminated | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients NCT03458728 | Bayer | Phase 1 / Phase 2 |
| Completed | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/R NCT03441360 | Eisai Inc. | Phase 2 |
| Completed | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in NCT03245450 | Eisai Inc. | Phase 1 / Phase 2 |
| Unknown | Irinotecan and Temozolomide for Ewing Sarcoma NCT03359005 | Peking University People's Hospital | Phase 2 |
| Active Not Recruiting | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or O NCT03373097 | Bambino Gesù Hospital and Research Institute | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas NCT03356782 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers NCT03190174 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies NCT04308330 | New York Medical College | Phase 1 |
| Terminated | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms T NCT02581384 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors NCT02982941 | MacroGenics | Phase 1 |
| Unknown | Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer NCT02856048 | Assistance Publique - Hôpitaux de Paris | Phase 2 / Phase 3 |
| Completed | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma NCT02945800 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumor NCT02536183 | AeRang Kim | Phase 1 |
| Terminated | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) NCT02624388 | University of Virginia | Phase 2 |
| Completed | A Study of IMRT in Primary Bone and Soft Tissue Sarcoma NCT02520128 | University College, London | N/A |
| Recruiting | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and S NCT02508038 | University of Wisconsin, Madison | Phase 1 |
| Unknown | Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas NCT02409576 | National University Hospital, Singapore | Phase 1 / Phase 2 |
| Completed | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temoz NCT02044120 | Sarcoma Alliance for Research through Collaboration | Phase 1 |
| Completed | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors NCT02076906 | AeRang Kim | Phase 1 |
| Unknown | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophos NCT02013336 | South Plains Oncology Consortium | Phase 1 |
| Completed | Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma NCT01858168 | Massachusetts General Hospital | Phase 1 |
| Unknown | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors NCT01807468 | Samsung Medical Center | Phase 2 |
| Withdrawn | A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refrac NCT01969942 | University of Louisville | Phase 1 |
| Terminated | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors NCT02100891 | Monica Thakar | Phase 2 |
| Terminated | Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma NCT01882231 | Vanderbilt-Ingram Cancer Center | N/A |
| Completed | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory S NCT01625351 | St. Jude Children's Research Hospital | Phase 1 |
| Terminated | Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma NCT01610570 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting NCT01492569 | Stanford University | N/A |
| Completed | Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors NCT01286987 | Pfizer | Phase 1 |
| Completed | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors NCT00931931 | Timothy Cripe | Phase 1 |
| Active Not Recruiting | Methionine PET/CT Studies In Patients With Cancer NCT00840047 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young NCT01780779 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcom NCT00743496 | St. Jude Children's Research Hospital | Phase 1 |
| Completed | Evaluating Dactinomycin and Vincristine in Young Patients With Cancer NCT00674193 | Children's Oncology Group | — |
| Completed | Collecting and Storing Tissue From Young Patients With Cancer NCT00898755 | Children's Oncology Group | — |
| Completed | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagn NCT00638898 | City of Hope Medical Center | Phase 1 |
| Completed | Machine Learning Applied to EHRs Data of Patients With Sarcoma NCT07215728 | University of Milano Bicocca | — |
| Completed | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study NCT00026780 | National Cancer Institute (NCI) | — |
| Completed | The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma NCT06659224 | asmaa salama ibrahim | — |
| Temporarily Not Available | Expanded Access of Vigil in Solid Tumors NCT03842865 | Gradalis, Inc. | — |
| No Longer Available | Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma NCT03029481 | Jonsson Comprehensive Cancer Center | — |